Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
Open Access
- 7 November 2023
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (11) , 1572
Abstract
Treatment-resistant depression (TRD) is a term used to describe a particular type of major depressive disorder (MDD). There is no consensus about what defines TRD, with various studies describing between 1 and 4 failures of antidepressant therapies, with or without electroconvulsive therapy (ECT). That is why TRD is such a growing concern among clinicians and researchers, and it explains the necessity for investigating novel therapeutic targets beyond conventional monoamine pathways. An imbalance between two primary central nervous system (CNS) neurotransmitters, L-glutamate and γ-aminobutyric acid (GABA), has emerged as having a key role in the pathophysiology of TRD. In this review, we provide an evaluation and comprehensive review of investigational antidepressants targeting these two systems, accessing their levels of available evidence, mechanisms of action, and safety profiles. N-methyl-D-aspartate (NMDA) receptor antagonism has shown the most promise amongst the glutamatergic targets, with ketamine and esketamine (Spravato) robustly generating responses across trials. Two specific NMDA-glycine site modulators, D-cycloserine (DCS) and apimostinel, have also generated promising initial safety and efficacy profiles, warranting further investigation. Combination dextromethorphan-bupropion (AXS-05/Auvelity) displays a unique mechanism of action and demonstrated positive results in particular applicability in subpopulations with cognitive dysfunction. Currently, the most promising GABA modulators appear to be synthetic neurosteroid analogs with positive GABAA receptor modulation (such as brexanolone). Overall, advances in the last decade provide exciting perspectives for those who do not improve with conventional therapies. Of the compounds reviewed here, three are approved by the Food and Drug Administration (FDA): esketamine (Spravato) for TRD, Auvelity (dextromethorphan-bupropion) for major depressive disorder (MDD), and brexanolone (Zulresso) for post-partum depression (PPD). Notably, some concerns have arisen with esketamine and brexanolone, which will be detailed in this study.Keywords
This publication has 176 references indexed in Scilit:
- Allopregnanolone regulates neurogenesis and depressive/anxiety-like behaviour in a social isolation rodent model of chronic stressNeuropharmacology, 2012
- A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive DisorderJournal of Clinical Psychopharmacology, 2012
- Novel glutamatergic agents for major depressive disorder and bipolar disorderPharmacology Biochemistry and Behavior, 2012
- How Inhibition Shapes Cortical ActivityNeuron, 2011
- Reduced somatostatin in subgenual anterior cingulate cortex in major depressionNeurobiology of Disease, 2011
- Depression, rumination and the default networkSocial Cognitive and Affective Neuroscience, 2010
- ΔFosB in brain reward circuits mediates resilience to stress and antidepressant responsesNature Neuroscience, 2010
- Rapid Enhancement of Glutamatergic Neurotransmission in Bipolar Depression Following Treatment with RiluzoleNeuropsychopharmacology, 2009
- Amino Acid Neurotransmitters Assessed by Proton Magnetic Resonance Spectroscopy: Relationship to Treatment Resistance in Major Depressive DisorderBiological Psychiatry, 2009
- Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzoleMolecular Psychiatry, 2008